Please login to the form below

Not currently logged in
Email:
Password:

afamelanotide

This page shows the latest afamelanotide news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Scenesse (afamelanotide) has not been launched in the UK, but the company has stated that the cost of an implant will be £12, 020 (excluding VAT).

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....

Infographics